Article can be read via the following link: https://www.businesswire.com/news/home/20250109147839/en/Cyrus-Biotechnology-Announces-Selection-of-CYR212-as-Clinical-Candidate-for-Chronic-IgG-driven-Autoimmune-Disease-Including-Myasthenia-Gravis-and-Immune-Thrombocytopenia
